L EYDIG CELL STEROIDOGENIC function is predominantly regulated by LH/human choriogonadotropin (hCG) and the influence of multiple signaling pathways (1) (2) (3) . The steroidogenic potential of Leydig cells can be modulated not only by LH/hCG but also by peptide and nonpeptide hormones, including growth factors, prostaglandins, and steroids, through endocrine, autocrine, and paracrine regulatory events (2, 4) . Growth factors are involved in numerous actions in many different cell types. IGF-I is a growth-promoting peptide, its effects being mediated through a transmembrane tyrosine kinase receptor that is structurally related to the insulin receptor, and modulates many biological functions including steroidogenesis in gonadal cells. However, the mechanism by which IGF-I influences the steroidogenic machinery in Leydig cells remains poorly understood.
The IGF-I system includes the IGF-I ligands (IGF-I and IGF-II), IGF-I receptors, and IGF-I binding proteins (5, 6) . Although most of the physiological functions of IGF-I are thought to occur via the IGF-I receptor, six identified IGF-I-binding proteins can bind IGF-I with varying affinities and can influence its activity (5, 6) . The binding of IGF-I to its receptor and the subsequent intracellular modifications that occur result in the activation of Ras-Raf-1-MAPKs, a family of serine/threonine kinases involved in regulating a diverse array of cellular and nuclear proteins, including transcription factors (4, 5) . The role of IGF-I has been demonstrated in testicular growth and development, control of Leydig cell numbers, and in the onset of steroidogenesis and spermatogenesis (2, 7) . Disruption of the gene encoding the IGF-I receptor resulted in developmental delays in reproductive organs, dwarfism, abnormalities in the central nervous system, and infertility in mice (8, 9) . In addition, increasing evidence is accumulating that LH/hCG action can also be controlled by various factors including IGF-l (2, 10, 11), suggesting that IGF-I is an important physiological regulator of testicular function.
Biochemical, immunocytochemical, and ligandbinding studies have identified the presence of IGF-I receptors in human (12) , porcine (13) , rat (14) , and mouse (15) Leydig cells. Treatment with IGF-I has been shown to potentiate steroidogenic responsiveness to LH/hCG or cAMP analogs in primary cultures of different Leydig cells (10, (16) (17) (18) . It has recently been demonstrated that IGF-I null mice have decreased levels of serum testosterone and steroidogenic acute regulatory (StAR) protein (19) , and thus, an investigation on the direct effects of IGF-I on StAR expression seems warranted. StAR is synthesized as a 37-kDa precursor mitochondrial phosphoprotein that is converted to a 30-kDa mature isoform after uptake and processing by the mitochondria (20) (21) (22) . StAR has been demonstrated to play an essential role in regulating steroid biosynthesis by mediating the transfer of cholesterol from the outer to the inner mitochondrial membrane where it is converted to pregnenolone (22) (23) (24) (25) . The precise role of StAR in the mechanism of cholesterol transfer to the inner mitochondrial membrane is unknown, but the preponderance of evidence indicates that the 37-kDa isoform acts on the outer membrane to effect cholesterol transfer (26, 27 ). An opposing view indicated that the 30-kDa phosphorylated isoform acting on the inner mitochondrial membrane resulted in the majority of cholesterol transfer (28) .
The compelling evidence documenting the critical role of StAR in the regulation of steroidogenesis has been obtained from both basic and clinical studies (23, 29, 30) . Transcriptional and/or translational inhibition of StAR expression results in a dramatic decrease in steroid biosynthesis whereas approximately 10-15% of steroid synthesis appears to be mediated through StAR-independent mechanisms (31) (32) (33) (34) . Whereas the expression of the StAR protein is predominantly regulated by cAMP-dependent mechanisms, several factors and signaling pathways have been demonstrated to play permissive roles (reviewed in Refs. 35 and 36) .
In addition to the cAMP/protein kinase A (PKA) pathway, the protein kinase C (PKC) pathway was demonstrated to be involved in regulating StAR expression and steroidogenesis in mouse Leydig (37) and adrenal (38, 39) cells. Also, transcriptional regulation of the StAR gene is mediated by several transcription factors (35, 40) , including the cAMP response element (CRE)-binding protein (CREB)/CRE modulator, and the activator protein 1 (AP-1) family members Fos and Jun (41) (42) (43) (44) (45) . Additional studies have also demonstrated the involvement of DAX-1 (dosage-sensitive sex reversal, adrenal hypoplasia congenita, critical region on the X chromosome, gene 1) and SR-BI (scavenger receptor, class B, type 1) in the regulation of StAR expression and steroidogenesis (46) (47) (48) (49) (50) . The present findings demonstrate that the mechanism of action of IGF-I in the regulation of StAR expression and steroid synthesis in mouse Leydig cells involves multiple signaling pathways.
RESULTS

Role of IGF-I on StAR, Cytochrome P450 SideChain Cleavage Enzyme (P450scc), 3␤-Hydroxysteroid Dehydrogenase (3␤-HSD), Steroid, and cAMP Levels
Growth factors are known to have diverse roles in regulating StAR expression and steroidogenesis in gonadal cells. Mouse Leydig tumor (mLTC-1) cells treated with 0-500 ng/ml IGF-I demonstrated dosedependent increases in StAR protein, StAR mRNA, and progesterone synthesis (Fig. 1) . IGF-I demonstrated 2.7 Ϯ 0.3-and 3.3 Ϯ 0.4-fold increases in StAR protein (Fig. 1, A and D) and StAR mRNA (Fig. 1 , B and D) levels over untreated cells, respectively. Accumulation of progesterone in the media was slightly lower when compared with StAR expression, being 2.0 Ϯ 0.3-fold over basal in response to IGF-I. In contrast, IGF-I did not affect P450scc protein expression (Fig. 1,  C and D) .
The temporal response of StAR, P450scc, and 3␤-HSD expression to IGF-I was examined by immunoblotting (Fig. 2) . mLTC-1 cells treated with 100 ng/ml IGF-I for 0-36 h demonstrated an increase (P Ͻ 0.05) in StAR protein expression at 2 h, reached a maximum of 2.9-fold at 6 h, and started decreasing with time thereafter (Fig. 2, A and D) . Under conditions that increased StAR expression, no significant effect of IGF-I on P450scc and 3␤-HSD expression was observed ( Fig. 2, B-D) . To affirm or refute a role for cAMP in IGF-I-mediated StAR expression and steroid synthesis, the levels of cAMP were determined. Cells treated with 100 ng/ml IGF-I for 0-6 h in the presence of 0.5 mM 3-isobutyl-1-methyl xanthine demonstrated no detectable differences in the levels of intracellular cAMP (Fig. 2D, inset ). These findings demonstrate that IGF-I is able to increase StAR expression and steroi-dogenesis in a dose-and time-dependent manner without affecting intracellular cAMP levels.
To determine whether the stimulatory effect of IGF-I on StAR expression was specific and not due to increased cell numbers, DNA synthesis was assessed in cells treated for 24 h with 10 and 100 ng/ml IGF-I. Cellular DNA content was not altered by IGF-I, having 5.97 Ϯ 0.14, 6.12 Ϯ 0.08, and 6.09 Ϯ 0.11 g/10 6 cells in control, and 10 and 100 ng/ml IGF-I, respectively.
The physiological relevance of the effects of IGF-I on StAR expression and steroidogenesis was further evaluated in isolated mouse Leydig cells. As determined by RT-PCR, treatment with 100 ng/ml IGF-I for 6 h resulted in a 2.2 Ϯ 0.3-fold increase in StAR mRNA expression over untreated cells (Fig. 3A) . The cAMP analog, N,OЈ-dibutyrl-cAMP [(Bu) 2 cAMP], an inducer of StAR expression through the PKA pathway, demonstrated a 3.8 Ϯ 0.5-fold increase in StAR mRNA expression over basal at a concentration of 0.5 mM. Accumulation of testosterone in the media was elevated to 166 Ϯ 9 and 214 Ϯ 12% by IGF-I and (Bu) 2 cAMP, respectively, when compared with control ( Fig. 3B) , further confirming the involvement of IGF-I in the steroidogenic response.
Role of IGF-I, Insulin, and (Bu) 2 cAMP on StAR Expression and Steroidogenesis
CAMP-dependent mechanisms are the predominant regulators of StAR protein expression. Hence, the Cells were incubated 100 ng/ml with IGF-I for 0-36 h and subjected to immunoblotting with specific antibodies (panels A-C), as described in Materials and Methods. Cells were also treated without or with 100 ng/ml IGF-I for 0-6 h in the presence of 0.5 mM 3-isobutyl-1-methylxanthine, and the levels of intracellular cAMP were determined (panel D, inset) by RIA (Ϯ SE, n ϭ 3). Representative immunoblots illustrate expression of StAR (panel A), P450scc (panel B), and 3␤-HSD (panel C) at indicated times. Integrated optical density values of each immunospecific band were quantified and presented in terms of fold response (panel D), which represent the mean Ϯ SE of three independent experiments. effects of IGF-I and insulin (a structurally related peptide) on (Bu) 2 cAMP-mediated StAR expression and steroid synthesis were studied (Fig. 4) . mLTC-1 cells treated with 100 ng/ml IGF-I and 1000 ng/ml insulin for 6 h resulted in 3.1-and 2.9-fold increases in StAR mRNA expression over untreated cells, respectively. These agents increased progesterone production by approximately 2-fold over basal (1.63 Ϯ 0.18 ng/mg protein). The effects of insulin on the steroidogenic response are similar to those of IGF-I (2, 5). (Bu) 2 cAMP (0.5 mM) increased the levels of StAR mRNA (10.2 Ϯ 0.7-fold) and progesterone (284 Ϯ 29-fold) over controls (Fig. 4, A and B) . It should be noted, however, that mLTC-1 cells secrete testosterone and thus, more closely resemble primary Leydig cells (51, 52). In these cells, IGF-I/ insulin resulted in a 1.7 Ϯ 0.2-fold increase (P Ͻ 0.05) in testosterone production, whereas the increase in response to (Bu) 2 cAMP over untreated cells was 62 Ϯ 11-fold (Fig. 4B) . Also, IGF-I and insulin further enhanced (Bu) 2 cAMP-stimulated StAR mRNA expression by approximately 15-fold, and enhanced progesterone and testosterone levels by 330-and 105-fold over basal levels, demonstrating that IGF-I has effects both at the level of its receptor as well as at steps beyond adenylyl cyclase activity. Addition of 5 g/ml cycloheximide to IGF-Iand insulin-stimulated cells, significantly diminished (P Ͻ 0.01) StAR expression and steroid levels (Fig. 4 , A-C), indicating the requirement for ongoing protein synthesis in IGF-I-and insulin-mediated steroidogenic responses. mLTC-1 cells were treated without (Control) or with 100 ng/ml IGF-I, 1000 ng/ml insulin, 0.5 mM (Bu) 2 cAMP, 5 g/ml cycloheximide (CHX), or in combination for 6 h as indicated (panels A-C). Total RNA was extracted for RT-PCR analysis, and a representative autoradiogram demonstrates the effects of these agents on StAR mRNA expression (panel A). Integrated optical density values of each band were normalized to the corresponding L19 bands. Progesterone (panel B) and testosterone (panel C) levels in the media of the same treatments were determined (ϮSE, n ϭ 3-5). Letters above the bars indicate that these groups differ significantly at least at P Ͻ 0.05.
IGF-I and StAR Gene Transcription
To better understand the involvement of IGF-I in StAR expression, StAR promoter activity was assessed (Fig.  5A ). mLTC-1 cells transfected with various 5Ј-flanking StAR promoter/reporter segments (Ϫ966/Ϫ1, Ϫ151/Ϫ1 and Ϫ96/Ϫ1 bp) displayed no noticeable effect in response to 100 ng/ml IGF-I. On the other hand, 0.5 mM (Bu) 2 cAMP resulted in a 3.6 Ϯ 0.5-fold increase in StAR reporter activity, a response further augmented by 2-fold in the presence of IGF-I. The Ϫ151/Ϫ1 StAR segment used represents the cAMP responsive region in the mouse StAR gene (41, 53) . Deletion of the segment from Ϫ151 to Ϫ96 decreased basal reporter activity but did not affect (Bu) 2 cAMP-or IGF-I plus (Bu) 2 cAMP-mediated responsiveness. These data demonstrate that elements responsive to IGF-I are not present in the promoter regions studied.
In additional studies, IGF-I regulation of the StAR gene in the presence of several transcription factors which bind to the Ϫ151/Ϫ1 bp region of the StAR promoter and are instrumental in StAR's transcriptional regulation (reviewed in Ref. 35 ) was examined. StAR promoter activity in 0.5 mM (Bu) 2 cAMP-stimulated mLTC-1 cells transfected with steroidogenic factor 1 (SF-1), CCAAT/enhancer-binding protein ␤ (C/ EBP␤), SREBP-1, GATA-4, and specific protein 1 (Sp1) expression plasmids was significantly increased (P Ͻ 0.05) over that seen in mock transfected cells (Fig. 5B ). Whereas 100 ng/ml IGF-I alone had no apparent effect on StAR promoter activity, it potentially increased the (Bu) 2 cAMP-stimulated response approximately 2-fold in cells transfected with SF-1, C/EBP␤, and GATA-4, demonstrating the importance of these factors in transcriptional activation of the StAR gene. In contrast, cells overexpressing SREBP-1 and Sp1 had little to no effect on IGF-I plus (Bu) 2 cAMP-mediated StAR reporter activity. Furthermore, the involvement of CREB and the AP-1 family member, c-Jun, on IGF-I-stimulated StAR gene expression is illustrated below. These results indicate that IGF-I and (Bu) 2 cAMP act on StAR gene transcription via distinct mechanisms.
Role of the PKA and PKC Pathways in IGF-I-and (Bu) 2 cAMP-Responsive StAR Expression
To understand signaling events in the IGF-I-mediated steroidogenic response, the roles of the PKA and PKC pathways were assessed in mLTC-1 cells (Fig. 6 ). Cells treated with 100 ng/ml IGF-I and 0.05 and 0.5 mM (Bu) 2 cAMP for 6 h demonstrated approximately 2.7-, 3.8-, and 8.6-fold increases in StAR protein levels in comparison with control, respectively (Fig. 6A ). (Bu) 2 cAMP (0.05 and 0.5 mM)-induced StAR protein expression was further augmented by 6.3-and 11.4-fold when cells were treated in combination with IGF-I. Inhibition of PKA activity with H-89 (25 M) significantly decreased (P Ͻ 0.05) basal and IGF-I-stimulated StAR expression, suggesting the involvement of endogenous cAMP in IGF-I-mediated steroidogenic responses because the latter had no effect on cAMP levels. Under similar experimental paradigms, progesterone levels were approximately 2-, 60-, and 276-fold higher over basal, with IGF-I and 0.05 and 0.5 mM (Bu) 2 cAMP, respectively (data not shown), and, when used in combination, they followed the pattern of StAR expression. These results prompted us to evaluate the The role of the PKC pathway in IGF-I responsiveness was also investigated and compared with (Bu) 2 cAMP (Fig. 6B ). mLTC-1 cells treated with 100 ng/ml IGF-I and 10 nM of a PKC activator, phorbol 12-myristate 13-acetate (PMA), resulted in 2.8-and 6.7-fold increases in StAR protein levels when compared with controls. The specific PKC inhibitor, GF-109203X (GFX, 20 M), strongly decreased StAR protein expression. Also, 10 nM PMA produced a 4.4 Ϯ 0.6-fold increase in progesterone synthesis over basal that was not elevated in the presence of IGF-I (data not shown). Even though PMA showed a marked increase in StAR protein expression, no PStAR could be detected with PMA or PMA plus IGF-I. In contrast, PMA in combination with (Bu) 2 cAMP significantly increased (P Ͻ 0.05) both StAR protein, P-StAR, and progesterone (not illustrated) levels, and these responses were markedly attenuated by 20 M GFX. GFX also affected basal StAR protein expression.
IGF-I responsive StAR mRNA expression demonstrated qualitatively similar results in association with the PKA and PKC signaling pathways ( To elucidate a role for the PKC pathway in IGF-Imediated steroidogenesis, StAR expression in response to PMA was determined and compared with IGF-I. Cells treated with 10 nM PMA showed a significant increase (P Ͻ 0.01) in StAR protein expression by 2 h and a maximum response (6.9-fold) by 6 h and thereafter declined slowly with time ( Fig. 7) . Using similar experimental paradigms, qualitatively similar results were obtained with StAR mRNA expression. In fact, the expression of StAR in response to IGF-I was very similar to that seen with PMA (compare Figs. 2A and 7A ). Inhibition of PKC with 20 M GFX markedly decreased PMA-stimulated steroidogenic responsiveness. Notably, addition of 5 g/ml cycloheximide to PMA-treated cells attenuated (P Ͻ 0.01) both StAR expression and progesterone synthesis (Fig. 7B) , an observation similar to IGF-I responsiveness (Fig. 4 , A-C). These findings demonstrate clearly that the PKC signaling pathway plays an indispensable role in IGF-I-mediated steroidogenic responses. The role of the PKA and PKC pathways on StAR mRNA expression using similar experimental conditions was determined. Cells were incubated without or with 100 ng/ml IGF-I, 0.05 and 0.5 mM (Bu) 2 cAMP, 10 nM PMA, 20 M GFX, and 25 M H-89, or a combination of them for 6 h, as indicated (panels A-C). Cells were subjected to mitochondrial isolation for determining StAR protein and P-StAR by immunoblotting, and total RNA for determining StAR mRNA expression by RT-PCR analysis. Representative immunoblots and autoradiogram show expression of StAR and P-StAR using 25 g of mitochondrial protein (panels A and B), and StAR mRNA expression using 2 g of total RNA (panel C). Data are representative of three independent experiments. kD, Kilodaltons.
IGF-I, (Bu) 2 cAMP, and ERK1/2 Signaling and Their Effect on StAR, DAX-1, and SR-BI Expression and Steroid Synthesis
To explore the molecular events involved in IGF-I signaling, the role of ERK1/2 (p44 and p42 MAPK) in IGF-I responsiveness was evaluated in mLTC-1 cells (Fig. 8) . Serum-starved cells treated with 100 ng/ml IGF-I increased ERK1/2 phosphorylation (P-ERK1/2) in a time-dependent manner (0-30 min). An increase in P-ERK1/2 was evident (P Ͻ 0.05) within 1 min, was maximal at 3 min, and decreased thereafter with time (Fig. 8A) . The amount of ERK1/2 protein was constant throughout this time course; however, the expression of ERK2 was more than 20 times higher when compared with ERK1. In additional experiments, treatment with 0-100 ng/ml IGF-I for 3 min resulted in a dosedependent elevation of P-ERK1/2 without affecting ERK1/2 protein levels (Fig. 8B ). The activation of P-ERK1/2 by 100 ng/ml IGF-I was analyzed using the MAPK/ERK (MEK) inhibitors PD98059 (PD, 50 M) and U0126 (U0, 12 M), both of which severely affected P-ERK1/2 (Fig. 8C) . However, PD and U0 did not affect expression of ERK1/2 protein. Thus, the alteration in the levels of P-ERK1/2 by IGF-I reflected increases in protein phosphorylation rather than protein synthesis.
The importance of IGF-I-induced ERK1/2 signaling on StAR expression and steroidogenesis was determined ( Fig. 9) . mLTC-1 cells treated with 100 ng/ml IGF-I for 6 h demonstrated a 2.8-fold increase in StAR protein expression over basal. Inhibition of MEK with 50 M PD and 12 M U0 was found to increase basal and IGF-I-stimulated StAR protein expression, but PStAR was undetectable. Progesterone production was attenuated by 42-56% under basal and stimulated conditions. These results are in agreement with the LH-mediated increase in StAR expression and decrease in steroid synthesis observed in primary and in mLTC-1 cells using these inhibitors (55). In contrast, 0.5 mM (Bu) 2 cAMP resulted in an 8.8-fold increase in StAR protein expression, a response that was elevated further (P Ͻ 0.05) with IGF-I and was correlated with P-StAR (Fig. 9B) . The increase in (Bu) 2 cAMP-mediated StAR expression and progesterone synthesis was inhibited (P Ͻ 0.01) by these MEK inhibitors, an observation consistent with previous studies using hCG (56) and forskolin (57) in Leydig cells. These results demonstrate that the role of MAPK/ERK in the steroidogenic response is largely associated with receptoreffector coupling in a stimulus-specific manner (56, 58) .
To obtain more insight into these mechanisms, the effect of MEK inhibitors on IGF-I and (Bu) 2 cAMP-responsive StAR expression was analyzed in relation to DAX-1 expression, as this transcription factor has been demonstrated to be inversely correlated to StAR expression (48, 50, 59). As depicted in Fig. 9C , the increase in StAR mRNA expression in response to 100 ng/ml IGF-I or 0.5 mM (Bu) 2 cAMP was associated with a decrease (P Ͻ 0.05) in DAX-1 mRNA compared with Cells were stimulated with 10 nM PMA for 0-36 h and subjected to immunoblotting (using 30 g of mitochondrial protein) and RT-PCR (using 2 g of total RNA) analysis for StAR expression (panel A), as described in the legend of Fig.  1 . Cells were also treated without (Control) or with 10 nM PMA for 6 h in the absence or presence of 5 g/ml cycloheximide (CHX), and StAR expression and progesterone accumulation in the media were then determined (panel B). Representative immunoblots and autoradiograms illustrate PMA-stimulated StAR protein and StAR mRNA expression (panels A and B). IOD values of each band were quantified (normalized with the corresponding L19 bands in the case of RT-PCR), and the levels of StAR protein and StAR mRNA are expressed as the maximum activity in terms of fold response (panel A). In both panels, data represent the mean Ϯ SE of three to four independent experiments. Letters above the bars indicate that these groups differ significantly at P Ͻ 0.05. controls. Treatment of cells with both 50 M PD and 12 M U0 increased basal and IGF-I-mediated StAR expression but decreased DAX-1 expression (Fig. 9C) . In contrast, (Bu) 2 cAMP-stimulated StAR mRNA expression was decreased in the presence of PD and U0 and was inversely correlated with DAX-1 expression, suggesting the involvement of DAX-1 in regulating StAR expression.
To further understand the decrease in steroid synthesis associated with MEK inhibition, we investigated the expression levels of the scavenger receptor class B type 1 (SR-B1), the lipoprotein receptor involved in providing steroidogenic cells with cholesterol for steroid biosynthesis. Treatment of 100 ng/ml IGF-I demonstrated a 1.8 Ϯ 0.3-fold increase in SR-B1 mRNA expression over basal (Fig. 9D) . In contrast, the expression of SR-BI mRNA was 6.2 Ϯ 0.6-fold in response to 0.5 mM (Bu) 2 cAMP when compared with controls. It can be clearly seen that both 50 M PD and 12 M U0 were capable of decreasing (P Ͻ 0.05) IGF-I and (Bu) 2 cAMP-stimulated SR-B1 mRNA expression. These inhibitors also affect basal SR-B1 expression. Thus, the decrease in steroid synthesis in response to PD and U0 could be a result of a decrease in cholesterol availability to the mitochondria as a result of an inhibition in SR-B1 expression.
CREB Phosphorylation and Transcriptional Activation of CREB by IGF-I
The role of posttranslational modification of a CREB/ CRE modulator family member in the regulation of StAR expression and steroidogenesis has been demonstrated (41, 43). Thus, it was essential to determine whether IGF-I plays a role in CREB phosphorylation. As depicted in Fig. 10A , phosphorylation of CREB (P-CREB) at Ser133 was increased by 3.6 Ϯ 0.7-fold over basal at 30 min in response to 100 ng/ml IGF-I and began to decrease thereafter with time. No changes were observed in the levels of CREB protein during this 180-min period. Also, the phosphoactivating-CREB antibody (Ab) detected an additional band for phosphorylated transcription factor 1 (P-ATF-1, Ser63), as both CREB and ATF-1 are 100% homologous for consensus phosphorylation sequences (60). Indeed, P-ATF-1 demonstrated an expression pattern similar to that of P-CREB. Additionally, 0-500 ng/ml IGF-I increased P-CREB and P-ATF-1 in a dose-response manner without affecting the total amount of CREB protein (Fig. 10B) .
The role of IGF-I in CREB phosphorylation and its relevance to StAR gene transcription were investigated. mLTC-1 cells transfected with wild-type CREB (WT-CREB) in the presence of the 151/Ϫ1 bp StAR reporter segment, exhibited an approximately 1.6-fold increase in luciferase activity with 0.5 mM (Bu) 2 cAMP, over the response seen in mock-transfected cells (Fig. 10C) . Whereas 100 ng/ml IGF-I by itself had no clear effect, it further augmented (Bu) 2 cAMP-induced (P Ͻ 0.05) StAR reporter activity. Cells transfected with either a nonphos- Cells were serum starved for 6 h and then treated with 100 ng/ml IGF-I for 0-30 min and ERK1/2 phosphorylation (P-ERK1/2) and total ERK1/2 in 25 g total protein were determined by immunoblotting. Representative immunoblots illustrate expression of P-ERK1/2 and ERK1/2 in response to IGF-I (panel A). Integral optical density (IOD) values presented for P-ERK1 (p44), P-ERK2 (p42), and ERK1/2 were compiled from four independent experiments (panel A). Serum-starved cells were incubated for 3 min with 0-100 ng/ml of IGF-I. and U0 (12 M) for 15 min, and then were divided into two groups. One group was incubated without (Control) or with 100 ng/ml IGF-I in the absence or presence of PD or U0 for 6 h (panel A). The other group was treated with 0.5 mM (Bu) 2 cAMP in the presence or absence of PD and U0, or in combination with IGF-I, (Bu) 2 cAMP, PD, and U0 for 6 h, as indicated (panel B). Representative immunoblots illustrate StAR protein expression and StAR phosphorylation (P-StAR) using 25 g of mitochondrial protein. Accumulation of progesterone in the media of these treatment groups was determined and expressed as ng/mg of protein (panels A and B). Similarly, mLTC-1 cells were treated for 6 h without (Control) or with IGF-I, (Bu) 2 cAMP, PD, U0, or their combination as indicated (panels C and D). Total RNA was isolated from different treatment groups and subjected to the expression of StAR, DAX-1, and L19 mRNAs (panel C), and SR-BI and L19 mRNAs (panel D) by RT-PCR analysis using 2.5 g of RNA. Integrated optical density (IOD) values of StAR, DAX-1, and SR-BI bands were quantified and normalized with the corresponding L19 bands and presented (panels C and D). Note the different scales on both sides (panel C). Data represent the mean Ϯ SE of three to four independent experiments. Letters above the bars indicate that these groups differ significantly at least at P Ͻ 0.05. cific transactivator plasmid, pFA2-c-Jun, in the presence of pFR-Luc demonstrated a dose-dependent increase in luciferase activity, a response enhanced maximally by 2.7 Ϯ 0.4-fold over basal with 100 ng/ml IGF-I (Fig. 11A ). Cells cotransfected with pFA2-c-Jun in the presence of a dominant-negative form of c-Jun (TAM-67) abrogated the c-Jun-mediated response to IGF-I.
To obtain more insight into these mechanisms, the effect of IGF-I on c-Jun phosphorylation was determined in mLTC-1 cells (Fig. 11B) . Cells treated with 100 ng/ml IGF-I resulted in an increase in c-Jun phosphorylation (P-c-Jun) in a time-dependent manner. Pc-Jun appeared as a doublet and was clearly elevated (P Ͻ 0.01) at 5 min, reached a maximum (7.2 Ϯ 0.9-fold) at 15 min, and decreased below control at 120 min. Phospho c-Jun Ab (Ser73) also detected phosphorylated Jun D (P-Jun D), both of which were temporally regulated by IGF-I.
The relevance of c-Jun phosphorylation in response to IGF-I was evaluated at the level of StAR gene transcription utilizing the Ϫ151/Ϫ1 StAR reporter segment (Fig. 11C) . mLTC-1 cells transfected with the c-Jun expression plasmid demonstrated an additional 2.2 Ϯ 0.4-fold increase in luciferase activity over the response seen with 0.5 mM (Bu) 2 cAMP in mock-transfected cells. In spite of a lack of IGF-I response, it further enhanced (Bu) 2 cAMP-induced (ϳ2 fold) StAR reporter activity mediated by c-Jun. The activation of c-Jun-mediated StAR reporter activity by (Bu) 2 cAMP was markedly inhibited by TAM-67, and IGF-I failed to modulate (Bu) 2 cAMP-stimulated responsiveness. Taken together, these findings demonstrate that IGF-I-responsive CREB and c-Jun signaling play essential roles in regulating StAR transcription, especially the synergy between IGF-I and (Bu) 2 cAMP, in mouse Leydig cells.
DISCUSSION
Steroidogenic responsiveness of gonadal cells to gonadotropins can be modulated by circulating peptides or locally produced factors secreted by cells within respective tissues. Basic and clinical studies implicate the role of growth factors in regulating testicular function, including spermatogenesis, and these factors can interact with LH/hCG in potentiating their action on Leydig cells. Steroidogenesis in Leydig cells involves a complex interaction of a diversity of hormones and multiple signaling pathways (2, 3, 31, 61) . Steroid hormone biosynthesis is initiated upon translocation of cholesterol from the outer to the inner mitochondrial membrane, the site of the P450scc enzyme, a process mediated by the StAR protein (23) (24) (25) . The present studies extend our knowledge of the manner in which IGF-I acts to drive StAR expression and the steroidogenic machinery in mouse Leydig cells. Panel A, mLTC-1 cells were treated with 100 ng/ml IGF-I for 0-180 min. Total cellular protein (30 g) was electrophoresed and immunoblotted, and representative immunoblots show CREB phosphorylation (P-CREB), ATF-1 phosphorylation (P-ATF-1), and CREB in response to IGF-I. Cells were also incubated with 0-500 ng/ml of IGF-I for 30 min, and 28 g of total protein was analyzed for P-CREB, P-ATF-1, and CREB by immunoblotting (panel B). Results are representative of three independent experiments. Panel C, mLTC-1 cells were transfected with empty vector (pcDNA3.1), wild-type CREB (WT-CREB), CREB-M1 (nonphosphorylatable CREB), and A-CREB (dominant-negative CREB), in the presence of the Ϫ151/Ϫ1 StAR promoter segment. Cells were cotransfected with pRL-SV40 for normalization of transfection efficiency. After 36 h of transfection, cells were treated without (Basal) or with 100 ng/ml IGF-I, 0.5 mM (Bu) 2 cAMP, or a combination of them for an additional 6 h, and luciferase activity in the cell lysates was determined and expressed as reporter response [RLU (relative light units)]. Data represent the mean Ϯ SE of four independent experiments.
Our current data demonstrate that IGF-I is capable of increasing expression of StAR protein, but not StAR phosphorylation, and steroid synthesis in mouse Leydig cells. The stimulatory effect of IGF-I on StAR expression and steroid synthesis was dependent on ongoing protein synthesis, and these responses were not associated with an alteration of intracellular cAMP (34, 62) . The steroidogenic potency of IGF-I was evident both in mLTC-1 and in freshly isolated mouse Leydig cells and was qualitatively similar to that of insulin, providing evidence that the two hormones are probably acting through similar mechanisms. The action of IGF-I on steroidogenesis in mLTC-1 cells was specific and was mediated through its own receptors because we demonstrated that they possess high-affinity IGF-I binding sites [dissociation constant (K d ) ϳ 0.68 nM] with a capacity of 172 fmol/mg protein as determined by Scatchard analysis (data not shown). Consistent with this finding, IGF-I receptors have previously been identified in Leydig cells of several species (12) (13) (14) (15) . Alterations in DNA synthesis were not observed with longer periods of IGF-I treatment, indicating that IGF-I may act as a differentiation factor rather than a mitogenic factor. Hence, the influence of the latter can be ruled out as a cause of the increased steroidogenic response in adult mouse Leydig cells (16) .
IGF-I and insulin are also capable of potentiating (Bu) 2 cAMP-mediated StAR expression and steroid synthesis in mouse Leydig cells, an observation in agreement with previous findings (16, 18, 63) . No significant effect of IGF-I was observed on either P450scc or 3␤-HSD protein levels in mLTC-1 cells. Likewise, IGF-I had no effect on P450scc mRNA expression, although it increases hCG-stimulated P450scc levels in primary cultures of rat Leydig cells (64, 65 ). An elevation of P450scc and 17␣-hydroxylase mRNA levels in porcine Leydig cells has also been reported (10) . The lack of an IGF-I/insulin response on basal and (Bu) 2 cAMP-mediated progesterone synthesis in MA-10 cells might be due to the absence of functional receptors for these ligands (66) . MA-10 and mLTC-1 are Leydig cells cloned from mouse tumors. The latter cell line secretes significant amounts of testosterone together with constitutively higher levels of progesterone, StAR, P450scc, and 3␤-HSD and thus more closely resembles primary Leydig cells (present data and Refs. 51, 52, and 67). Therefore, the steroidogenic potential of IGF-I is dependent upon the relative abundance of receptors and receptor-ligand interactions, the endocrine status of the donor, species specificity, and the short-or long-term experimental conditions.
Mapping of the mouse StAR promoter demonstrated the importance of the first 150 nucleotides from the transcription start site, which contains multiple recognition motifs for sequence-specific transcription factors, in transcriptional regulation of the StAR gene (35, 40, 42, 45, 53, (68) (69) (70) . In the present study, no noticeable effect of IGF-I on StAR promoter activity was found up to 1 kb of the 5Ј-flanking region, sug- gesting that element(s) responsive to IGF-I may lie upstream of this segment or in intronic sequences of the gene (71, 72) . However, IGF-I potentiated the response of (Bu) 2 cAMP in StAR promoter responsiveness with the segments that responded to (Bu) 2 cAMP. Additionally, we observed that several transcription factors were involved in regulating transcription of the StAR gene mediated by IGF-I, including SF-1, C/EBP␤, GATA-4, CREB, and c-Jun. Consistent with this, the regulation of porcine StAR promoter activity by IGF-I has been shown to occur in conjunction with GATA-4 and C/EBP␤ (73) . However, it also remains possible that IGF-I can modulate signaling pathways downstream of cAMP/PKA that are involved in the steroidogenic response.
Whereas the cAMP/PKA pathway is undoubtedly the major signaling cascade regulating StAR expression and steroidogenesis, several other pathways are involved in these processes as well (35, 36) . Earlier and present findings demonstrate that a low level of cAMP is sufficient for expression of the StAR protein (34, 74) , most notably phosphorylated StAR, and increasing steroid synthesis. Whereas intracellular cAMP was not affected by IGF-I, the PKA inhibitor H-89 decreased basal and IGF-I-mediated StAR expression, demonstrating that endogenous cAMP plays an essential role in IGF-I responsiveness. Previous studies have demonstrated an indispensable requirement for phosphorylation of StAR to attain its full biological activity (54, 75). Two putative conserved PKA phosphorylation sites (Ser56/57 and Ser194/195, in murine and human StAR, respectively) were identified and characterized, and the predominant involvement of the latter site in enhancing the activity of the StAR protein and steroidogenesis was illustrated (54). Utilizing a specific Ab against phosphorylated Ser194 in the StAR protein, no P-StAR was detected in response to IGF-I. On the other hand, (Bu) 2 cAMP greatly increased P-StAR, a response further augmented by IGF-I, demonstrating a critical role for phosphorylation in obtaining maximal steroid synthesis (54, 75, 76) . Importantly, the IGF-I response was found to be dependent on PKC signaling, as inhibition of PKC by GFX markedly decreased StAR expression and steroidogenesis. In addition, PMA increased StAR protein expression but not PStAR and only slightly elevated steroid production, a situation similar to that seen with IGF-I. Both IGF-I and PMA demonstrated a qualitatively parallel pattern in StAR expression that was dependent on ongoing protein synthesis. Whereas IGF-I potentiated the action of (Bu) 2 cAMP, it had no additional effects in combination with PMA. This observation indicates that the action of IGF-I in steroidogenesis is predominantly mediated through the PKC pathway in mouse Leydig cells.
The MAPK/ERK signaling cascade has been demonstrated to regulate StAR expression and steroidogenesis; however, conflicting reports are found in different steroidogenic cells (34, (55) (56) (57) (58) (77) (78) (79) . For example, inhibition of MEK activity with PD and U0 has been shown to be associated with stimulation (59, 77), inhibition (34, 56, 57) , or no effect (78-80) on the steroidogenic response. Our data demonstrate that activation of ERK1/2 phosphorylation in response to IGF-I was diminished by PD and U0 without affecting ERK1/2 protein synthesis. However, MEK inhibition increases basal and IGF-I-mediated StAR expression, but decreases progesterone synthesis. This seeming contradiction can be explained by previous findings and could be associated with stimulus specificity, as inhibition of MEK was demonstrated to enhance basal and LH-induced StAR expression but attenuate steroid synthesis both in primary and in mouse Leydig tumor cells (55). In the present study, it was also demonstrated that MEK inhibitors were capable of decreasing (Bu) 2 cAMP-responsive StAR expression and steroid synthesis, an observation in agreement with previous studies (34, 56, 57) . In a recent study, PD was demonstrated to have no effect on (Bu) 2 cAMPstimulated StAR expression in MA-10 cells (81) . In granulosa cells, inhibition of MEK has been shown to be associated with increases in basal and LH/FSHmediated StAR expression and steroid biosynthesis (59, 77) . Furthermore, whereas PD markedly attenuated IGF-I-induced progesterone production, no apparent effect of this inhibitor was found in insulinstimulated human granulosa cells (78) . These findings demonstrate a complex role for the MAPK/ERK cascade in the regulation of the steroidogenic response that appears to be dependent on receptor-effector coupling and is tissue and stimulus specific. Thus, it is plausible that activation of the ERK1/2 cascade with IGF-I and (Bu) 2 cAMP involves discrete signaling events and indicates the importance of other factor(s) in the steroidogenic response. Exploration of IGF-Iand (Bu) 2 cAMP-responsive StAR expression and steroid synthesis in association with MEK inhibition demonstrated that induction and/or attenuation of StAR expression was inversely correlated with DAX-1 (48, 59). In agreement with this, we recently demonstrated the involvement of DAX-1 in the regulation of steroidogenesis and StAR expression in mouse MA-10 and rat R2C Leydig tumor cells (50). PD and U0 decreased the expression of SR-BI, possibly inhibiting the availability of mitochondrial cholesterol and resulting in an attenuation of steroid synthesis. Studies are currently underway to determine whether other factors, in addition to DAX-1 and SR-BI, might influence the MEKassociated regulation of StAR expression and steroidogenesis in mouse Leydig cells.
The binding of IGF-I to its receptor in the plasma membrane results in receptor autophosphorylation, phosphorylation of intracellular proteins, receptor clustering, and differentiation of target cells (4) (5) (6) . Our data show that IGF-I induces phosphorylation of the transcription factor CREB at Ser133. This posttranslational modification of CREB, leading to an increase in StAR gene transcription, was markedly diminished by a nonphosphorylatable CREB (Ser 133 Ala) and a dominant-negative A-CREB (41, 43). IGF-I was capable of increasing phosphorylation of the AP-1 family mem-ber, c-Jun, and the importance of this phenomenon in StAR's transcriptional regulation was demonstrated using a dominant-negative TAM-67 that drastically affected c-Jun responsiveness. It is interesting to note that inhibition of CREB and c-Jun responsiveness abrogated the synergy between IGF-I and (Bu) 2 cAMP on StAR gene expression. The role of IGF-I in CREB phosphorylation and its relevance in transcription has been previously shown in PC12 neuronal cells (82) . In earlier studies we demonstrated that Fos and Jun could bind to the CRE2 site in the StAR promoter and were involved in StAR gene regulation (44). Moreover, peptide-mapping studies demonstrate that MAPK-related proteins can interact with AP-1 transcription factors, especially c-Jun (83) . Thus, the cooperation and/or interaction of different signaling pathways may represent cross-talk, a well-known event in signal transduction, which appears to link IGF-I responsive StAR expression and steroidogenesis in Leydig cells.
Taken together, these findings demonstrate the involvement of multiple IGF-I signaling events associated with the regulation of the steroidogenic machinery in mouse Leydig cells. The lack of StAR phosphorylation in response to IGF-I indicates the importance of phosphorylation at Ser194 in obtaining maximal activity of the StAR protein in steroid synthesis. The steroidogenic potential of IGF-I (or related growth factors) in modulating cAMP-induced StAR transcription mediated by different transcription factors, especially by CREB and c-Jun, undoubtedly involves a multitude of processes, many of which remain to be determined.
MATERIALS AND METHODS
Plasmids, Transfections, and Reporter Assays
The 5Ј-flanking regions (Ϫ966/Ϫ1, Ϫ151/Ϫ1, Ϫ96/Ϫ1) of the mouse StAR gene were cloned into the pGL3 basic vector (Promega Corp., Madison, WI), upstream of a luciferase reporter gene utilizing the XhoI and HindIII sites as described previously (41, 43) . The identities of the inserted fragments were verified by restriction endonuclease digestion and by automated sequencing with a PE Biosystem 310 Genetic Analyzer (ABI PRISM 310, PerkinElmer, Norwalk, CT). The wild-type CREB (WT-CREB) (41, 43) , nonphosphorylatable CREB (CREB-M1, Ser 133 Ala) (41, 43), dominant-negative CREB (A-CREB) (41), c-Jun, dominant-negative c-Jun (TAM-67) (44), SF-1 (69, 84) , C/EBP␤ (69), GATA-4 (85), Sp1 (86) , and SREBP-1 (87) expression plasmids have been previously described. An expression vector for the firefly luciferase reporter gene (pFR-Luc) was obtained from Stratagene (La Jolla, CA). The plasmid (pRL-SV40) containing the Renilla luciferase gene driven by simian virus 40 promoter (Promega) was used to normalize transfection efficiency.
Mouse Leydig tumor [mLTC-1; (88)] cells were obtained from American Type Culture Collection (Manassas, VA) and maintained in RPMI 1640 medium (Invitrogen Corp., San Diego, CA), containing serum and antibiotics (34, 41) . Transfection studies were carried out using FuGENE 6-transfection reagent (Roche Diagnostics, Indianapolis, IN) under optimized conditions (41, 43) . In brief, cells were cultured in either 12 or six-well plates to 65-75% confluency and transfected using 1-2 g of plasmid (or with 1:1 ratio where appropriate), in the presence of 12-20 ng of pRL-SV40. After 36 h of transfection, cells were treated as specified in different experiments.
Luciferase activity in the cell lysates was determined by the Dual-luciferase reporter assay (Promega). Briefly, after treatment cells were washed with 0.01 M PBS and 200-275 l of the reporter lysis buffer was added to the plates. The cellular debris was pelleted by centrifugation at 14,000 ϫ g at 4 C, and the supernatant was measured for relative light units (luciferase/Renilla) in a TD 20/20 Luminometer (Turner Designs, Sunnyvale, CA), following the instructions of the manufacturer.
Isolation and Purification of Mouse Leydig Cells
Isolation and purification of testicular Leydig cells from adult mouse (C57BL/6 strain, 2-3 months of age) were carried out utilizing previously described procedures (89, 90) . In brief, decapsulated interstitial cells were dispersed by collagenase (0.2%, 20 min, 34 C), filtered through sterile nylon gauze (0.5-0.8 mm mesh), and washed with DMEM/F12 medium to remove the collagenase. Cells were then purified using continuous Percoll density gradient (range 1.01-1.126 kg/liter) centrifugation. During centrifugation, cell types partitioning at approximately 1.07 kg/liter of Percoll were collected and washed, and 70-80% of the cells were Leydig cells as determined histochemically by 3␤-HSD staining. Cells were subcultured in DMEM/F12 medium containing antibiotics and used for experiments after 48 h.
RNA Extraction and Quantitative RT-PCR
Total RNA was extracted using Trizol reagent (Invitrogen Life Technologies, Carlsbad, CA) from different treatment groups. Isolation and amplification of mouse StAR cDNA was carried out utilizing the following primer pairs: the sense, 5Ј-GACCT-TGAAAGGCTCAGGAAGAAC-3Ј, and the antisense, 5Ј-TAGCTGAAGATGGACAGACTTGC-3Ј (22), as described previously (41, 90) . The primers used for DAX-1 (GenBank accession no. NM_007430) and SR-BI (GenBank accession no. U76205) were: DAX-1 sense, 5Ј-GCCGAGGGCCCCCT-GGTGGGAC-3Ј and, DAX-1 antisense, 5Ј-TCCAGCAT-CATATCATCCATGCTGAC-3Ј, and SR-BI sense, 5Ј-CT-CATCCAAGCAGCAGGTGCTCAAGAA-3Ј
and, SR-BI antisense, 5Ј-TGTTTGCCAACGGGTCCGTCTACCCACC-3Ј, respectively. The variation in RT-PCR efficiency was assessed using the L19 ribosomal protein gene as an internal control, using the sense primer 5Ј-GAAATCGCCAATGC-CAACTC-3Ј and the antisense primer 5Ј-TCTTAGACCTGC-GAGCCTCA-3Ј (91) .
RT and PCR were run sequentially in the same assay tube using 2-2.5 g of total RNA as specified in the figure legends, and the parameters including the number of cycles used for StAR, DAX-1 and SR-BI were optimized to be in the exponential phase (41, 67, 90) . The cDNAs generated were further amplified by PCR using the primer pairs listed above. The molecular sizes of StAR, DAX-1, SR-BI, and L19 were determined on 1.2% agarose gels, which were vacuum dried and exposed to x-ray film (Marsh Bio Products, Inc., Rochester, NY) for 1-3 h. The levels of StAR, DAX-1, SR-BI, and L19 signals were quantified using a computer-assisted image analyzer (Visage 2000, BioImage, Ann Arbor, MI).
Immunoblotting
Immunoblotting studies were carried out with either total cellular or mitochondrial proteins. Cells were sonicated in lysis buffer [50 mM Tris; 150 mM NaCl; 1% Nonidet P-40 (pH 7.4)], containing protease inhibitors (1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 2 g/ml leupeptin, 2 g/ml aprotinin) at 4 C. Mitochondria were isolated by differential centrifugation in TSE buffer (10 mM Tris; 250 mM sucrose; 100 mM EDTA, pH 7.4) containing protease inhibitors, as described previously (22, 41, 84) .
Protein (20-30 g ) was solubilized in sodium dodecyl sulfate (SDS) sample buffer and loaded onto a 12% SDS-polyacrylamide gel (Mini Protean II System, Bio-Rad Laboratories, Inc., Hercules, CA), as described by Laemmli (92) , with minor modifications (41, 90) . Electrophoresis was performed at 200 V for 1 h, and the proteins were electrophoretically transferred onto Immuno-Blot PVDF Membrane (Bio-Rad). The membranes were incubated overnight at 4 C in blocking buffer (Tris-buffered saline containing 0.2% Tween 20 and 4% Carnation nonfat dry milk) and incubated for 2 h with primary antibodies to StAR protein (aa 88-98) (22) and phospho-StAR (aa 190-199) generated in rabbits. It should be noted that the former Ab cannot distinguish between nonphosphorylated and phosphorylated StAR and thus detects total StAR protein. The Ab detecting StAR phosphorylation was generated against a peptide conjugated to keyhole limpet hemocyanin corresponding to aa 190-199 of mouse StAR with Ser194 phosphorylated. This was produced on a fee-for-service basis (Bethyl Laboratories, Montgomery, TX), and serum samples were double affinity purified using nonphosphorylated and phosphorylated peptides. Other primary antibodies used in immunoblotting were obtained from the following sources: P450scc (Chemicon International, Inc., Temecula, CA); 3␤-HSD (a generous gift from Dr. C. R. Parker, University of Alabama at Birmingham, Birmingham, AL); phospho ERK1/2, phospho CREB, and CREB (Cell Signaling Technologies, Beverly, MA); ERK1/2 (BD Biosciences Pharmingen, San Diego, CA); phospho c-Jun (Upstate Biotechnology, Inc., Lake Placid, NY); and c-Jun (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). After incubation with primary antibodies, the membranes were washed and incubated with appropriate secondary antibodies for 1.5 h and washed again, after which immunodetection of proteins was performed with the Chemiluminescence Imaging Western Lightning Kit (PerkinElmer, Boston, MA). The membranes were exposed to x-ray films (Marsh Bio Products), and the intensity of immunospecific bands was quantified by scanning (Visage 2000). Expression of phosphorylated and total proteins was assessed using identically processed membranes; however, where appropriate, the same membranes were also analyzed by stripping and reprobing.
Path-detect Trans-reporting Assay
mLTC-1 cells were transfected with the transactivator plasmid (pFA2-c-Jun) in the presence of a reporter plasmid (pFRLuc) using the FuGENE 6 transfection reagent (Roche Diagnostics), and the effect of IGF-I on c-Jun signaling was determined (Stratagene). The transactivator protein consists of the activation domain of c-Jun (aa 1-223) fused with the Gal4 DNA binding domain (aa 1-147), which were driven by the cytomegalovirus promoter. The pFR-Luc plasmid contains a synthetic promoter of the yeast Gal4 binding sites that control expression of the firefly luciferase gene. Upon cotransfection, the DNA binding domain of the fusion transactivator protein binds to the reporter plasmid at the Gal4 binding sites, and phosphorylation of the transcription activation domain of the fusion transactivator protein by IGF-I will activate transcription of the luciferase gene and indicate the involvement of this specific pathway. Cells were also cotransfected with a dominant-negative form of c-Jun, TAM-67, to determine the functional specificity of c-Jun in IGF-I signaling. After 36 h of transfection, cells were treated with 0-100 ng/ml of IGF-I for 6 h, and luciferase activity in the cell lysates was determined using a TD 20/20 Luminometer (Turner Designs).
Determination of DNA Synthesis
To determine the mitogenic effect of IGF-I, mLTC-1 cells were plated at a density of 1 ϫ 10 5 cells per well in six-well plates (89) . Cells were cultured in the absence or presence of 10 and 100 mg/ml IGF-I for 6 h. [ 3 H]thymidine (2 Ci/well; Amersham, Aylesbury, UK) was added to the cells, and incubation was continued for an additional 18 h. Thereafter, cells were washed with 0.01 M PBS, treated with 10% trichloroacetic acid at 4 C, lysed using 0.3 N NaOH containing 1% SDS, and counted in a ␤-spectrometer (LKB Wallac OY, Turku, Finland).
Statistical Analysis
All experiments were carried out in triplicate or quadruplicate and were repeated three to five times. The results are expressed as the mean Ϯ SE. Data were analyzed by ANOVA followed by Fisher's least-significant difference tests using Statview 5.1 program (Abacus Concepts, Inc., Berkeley, CA). Differences were regarded as significant at P Ͻ 0.05. 
